Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Integrity™ iCELLis™

Product Image
Product Description

iCELLis™, the world’s first fully integrated high-cell density bioreactor is designed to simplify your process, by combining the advantages of single-use technologies with the benefits of a fixed-bed system. Thanks to its compact design - for a quick implementation and more ease of use – iCELLis represents the new generation single-use bioreactors.

Central to the iCELLis bioreactor technology is the use of a compact fixed-bed, filled with custom macrocarriers. This matrix is made of medical grade polyester microfibers and provides in only 25L volume, up to 500m² growth area available to the cells. This surface is equivalent to the surface of 3000 Roller Bottles (1700cm² each). iCELLis bioreactors are supplied pre-packed with macrocarriers. Compared to standard stirred tank bioreactor using microcarriers, the iCELLis technology leads to a dramatic simplification of cell culture process. It enables to avoid delicate and time consuming manual operations: sterilization and hydration of microcarriers, and bead-to-bead transfers from preculture to final process.

With the biomass multiplication occurring in the fixed-bed, iCELLis bioreactors can be inoculated at very low density. The number and volume of pre-culture steps are reduced considerably: 20 Roller Bottles (1700 cm²) are can be sufficient to inoculate an iCELLis 500 bioreactor (500 m² of available surface to the cells). As a consequence of this process simplification, manual operations and associated costs are reduced dramatically.

Evenly-distributed media circulation is achieved by a built-in magnetic drive impeller, ensuring low shear stress and high cell viability. The cell culture medium flows through the fixed-bed from the bottom to the top. At the top, the medium falls as a thin film down the outer wall where it takes up O2 to maintain high KL.a. in the bioreactor. This unique waterfall oxygenation, together with a gentle agitation and biomass immobilization, enables compact iCELLis to achieve and maintain high-cell densities, equaling the productivity of much larger stirred tank units.

Process simplification, from vial thawing to final product, is at the heart of the iCELLis platform. As cells are immobilized in the fixed-bed and iCELLis operates in perfusion mode, there is no need for centrifugation to harvest the cells, which simplifies further the downstream process. Last but not least, in order to reduce process development time, the perfusion device is integrated into the iCELLis™ skid.

Product Integrity™ iCELLis™
Company ATMI LifeSciences
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

ATMI LifeSciences
10851 Louisiana Avenue South Bloomington, Minnesota 55438 USA

Tel: +1.952.942.0855
Fax: +1.952.516.5465



Scientific News
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
Study Reveals New Method to Develop More Efficient Drugs
A new study suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!